The investigation was concerned with design and characterization of oral immediate release tablets of Efavirenz, in order to improve efficacy and better patient compliance. Efavirenz is an antiretro viral drug a NNRTI of HIV-1. Efavirenz is a non-competitive inhibitor of HIV-1 reverse transcriptase (RT) and does not significantly inhibit HIV-2 RT or cellular DNA polymerases (α, β, γ or δ). Immediate Release tablet of Efavirenz drug was formulated by direct compression using super disintegrants like croscarmellose sodium, sodium starch glycolate, Crospovidone and microcrystalline cellulose.The drug-excipients interaction was investigated by FTIR. The granules and tablets of Efavirenz were evaluated for various pre and post compression parameters like Angle of repose, Compressibility index, Hausner’s ratio, Tablet hardness, Friability, Weight variation, Drug content and in-vitro dissolution. During the course of study it was found that the formula F7 containing croscarmellose sodium as disintegrant exhibited acceptable disintegration time, percentage drug content per tablet and in vitro drug release. Later they were subjected to stability studies after packing in amber colored PVC-PVDC blister packing which showed acceptable results.
Loading....